However in neuroblastoma, in pre-clinical studies, co-targeting of retinoid and TGFβ signaling pathways through combination of retionoic acid and Kartogenin (TGFβ signaling activating molecule) has decreased the viability of MYCN amplified neuroblastoma cells. This evidence concerns the gene MYCN and neuroblastoma.